Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05495152

PHASE3

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Sponsor: Henan Cancer Hospital

View on ClinicalTrials.gov

Summary

No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node metastasis following initial surgery for esophageal squamous cell carcinoma (ESCC).Controversy still exists regarding the role of adjuvant immunotherapy for ESCC patients who do not achieve pCR after neoadjuvant chemotherapy plus surgery and clinical T1-2 N0 patients with incidental pathologic lymph node metastasis following initial surgery. To investigate the outcomes of adjuvant Sintilimab in patients with locally advanced ESCC, we initiated this randomized controlled trial (RCT).

Official title: Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma: a Multi-Centre, Open-Label, Randomized, Controlled, Clinical Trial (HCHTOG2203)

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

219

Start Date

2022-08-01

Completion Date

2028-08-31

Last Updated

2024-10-02

Healthy Volunteers

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Sintilimab

Patients in adjuvant arm receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.

Inclusion Criteria: 1. Histologically proven squamous cell carcinoma. 2. Tumours are located in the thoracic oesophagus. 3. Age is between 18 years and 70 years. 4. ECOG performance status of 0 or 1. 5. Patients with resectable cT1-4aN+M0 or T3-4aN0M0 disease and residue disease is found after neoadjuvant chemotherapy plus surgery or cT1-2N0M0 and pathologically proven T1-2N+M0 after upfront surgery. 6. No metastatic cervical lymph nodes. 7. R0 resection is achieved by the minimally invasive esophagectomy (MIE) or open McKeown approach with total two-field lymph nodes dissection or three-field lymph nodes dissection. 8. No prior therapy was administered against other cancers. 9. Adequate bone marrow function: white blood cell count ≥ 4×109/L; absolute neutrophil count (ANC) ≥ 1.5×109/l; platelets ≥ 100×109/L; haemoglobin ≥ 9 g/dl. 10. Adequate liver function: serum bilirubin ≤ 1.5 × upper limit of normal (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.0 × ULN (ULN as per institutional standard). 11. Adequate renal function: glomerular filtration rate ≥ 60 ml/min calculated using the Cockcroft-Gault formula. 12. Normal thyroid function. 13. Written consent is obtained. Exclusion Criteria: 1. Patients receive neoadjuvant chemoradiation therapy. 2. Patients with pathological complete response (pCR). 3. No. of lymph node dissection \< 15. 4. Patients with clinical stages T1-2N+M0 and receive upfront surgery. 5. Patients with unresectable disease (bulky metastatic lymph nodes or T4b) and receive induction chemotherapy. 6. Patients requiring systemic steroid medication. 7. Patients with severe postoperative complications and not suitable for adjuvant therapy. 8. Synchronous or metachronous (within 5 years) double cancers. 9. Patients ever received immunotherapy. 10. Active infection requiring systemic therapy. 11. Patients ever received organ transplant or allogenic haemopoietic stem cell transplantation. 12. Patients with human immunodeficiency virus (HIV) infection. 13. Psychiatric disease. 14. Pregnant or lactating women or women of childbearing potential. 15. Hypersensitivity for Sintilimab.

Locations (2)

Henan Cancer Hospital

Zhengzhou, Henan, China